Clearmind Medicine Inc.
CMND · NASDAQ
10/31/2024 | 10/31/2023 | 10/31/2022 | 10/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.34 | 0.03 | -0.55 | -0.16 |
| FCF Yield | -2.82% | -21.31% | -1.23% | -1.17% |
| EV / EBITDA | -20.78 | -2.77 | -48.86 | -70.25 |
| Quality | ||||
| ROIC | -269.56% | -890.62% | 588.06% | -76.56% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.92 | 1.01 | 0.74 | 1.04 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 22.90% | -23.77% | -66.04% | -1,017.21% |
| Safety | ||||
| Net Debt / EBITDA | 0.82 | 0.62 | 0.01 | 1.25 |
| Interest Coverage | -221.21 | 0.00 | -433.61 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | -1.38 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -4,261.07 | -3,304.52 | -39,952.46 |